CellSource Co

CellSource Co Capital Intensity

The Capital Intensity Ratio of CellSource Co (4880.T) as of Nov 5, 2026 is 191.65 %. In the previous year, Capital Intensity Ratio was 164.60 % — a change of 16.43% (higher).

Capital Intensity

191.65 %

YoY

16.43%

Last updated:

Capital Intensity Ratio of CellSource Co is 2025 191.65 % . Capital Intensity Ratio of CellSource Co was 2024 164.60 % . It decreases by 16.43% higher compared to the previous year.

The CellSource Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
57.47 JPY
Jan 1, 2019
114.89 JPY
Jan 1, 2020
126.77 JPY
Jan 1, 2021
115.18 JPY
Jan 1, 2022
107.66 JPY
Jan 1, 2023
152.79 JPY
Jan 1, 2024
164.60 JPY
Jan 1, 2025
191.65 JPY
The CellSource Co Capital Intensity history
YEARCapital IntensityYoY
191.65 %+16.43%
164.60 %+7.73%
152.79 %+41.91%
107.66 %-6.53%
115.18 %-9.14%
126.77 %+10.34%
114.89 %+99.89%
57.47 %-8.88%
63.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Capital Intensity Ratio of CellSource Co is 191.65 % in 2025.

Capital Intensity Ratio of CellSource Co changed from 164.60 % to 191.65 %, representing a 16.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's CellSource Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CellSource Co

All Key Metrics — CellSource Co